Tirzepatide is a prescription medicine given as a once weekly injection under the skin. In the United States it is sold under two brand names marketed by Eli Lilly: one approved for type 2 diabetes and one approved for chronic weight management and, in adults with obesity, obstructive sleep apnea. It is not available over the counter, and it is not insulin. Copies made by compounding pharmacies also circulate through telehealth programs, and those are a different product category with different rules. This page explains what the official labeling says, in everyday language, plus what actually drives the monthly cost.
If you are weighing this drug against other injectable options, our ranked breakdown of Comparing GLP-1 Telehealth Programs covers how programs differ on price, labs and follow up. The rest of this guide sticks to the medicine itself.
What tirzepatide is and who it is prescribed for
Tirzepatide belongs to a newer drug class described on the label as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. In plain terms, it copies the action of two gut hormones instead of one. Older medicines in this family, including semaglutide, act on the GLP-1 receptor alone.
The diabetes brand is approved as an addition to diet and exercise to improve blood sugar control in adults and in children aged 10 years and older with type 2 diabetes. The weight management brand is approved for adults with obesity, or adults who are overweight and also have a weight related health condition, again alongside diet and physical activity. It also carries an approval for moderate to severe obstructive sleep apnea in adults with obesity. For an official plain-language summary of the diabetes use, the US National Library of Medicine keeps a patient drug page at MedlinePlus tirzepatide injection.
Two things follow from that. First, the brand you are prescribed depends on why you are being treated, not on which one a clinic prefers. Second, anything outside those indications, such as using it purely for cosmetic weight loss at a lower body weight, is off label. Off label prescribing is legal, but it is a clinical judgment call, not an approved use, and it can change how insurers respond.
Body mass index is one of the screening numbers most weight programs check before prescribing. If you want to know where you sit before an intake form asks:
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
How the dual hormone action works in the body
GIP and GLP-1 are hormones your gut releases after you eat. Tirzepatide activates both receptors, which produces several effects at once. It prompts the pancreas to release insulin when blood sugar is high, and it lowers glucagon, a hormone that raises blood sugar. Because that insulin release is glucose dependent, the drug alone is less likely to push blood sugar too low than insulin or sulfonylureas are.
It also slows how quickly the stomach empties and acts on appetite signaling in the brain. Most people describe feeling full sooner, staying full longer, and thinking about food less. That combination is why the same molecule can improve A1C, a three month average of blood sugar, and also reduce body weight. A detailed clinical summary of the mechanism and trial evidence is published in the StatPearls monograph hosted by NCBI.
Slowed stomach emptying explains a lot of the side effect profile too. Nausea, fullness and constipation are not random; they are the same mechanism turned up too high. It also explains why dose increases are spread out over weeks rather than days.
Dosing and titration: what the label describes
Both brands are once weekly, injected under the skin of the abdomen, thigh or upper arm, on the same day each week. The labeling describes starting at a low dose of 2.5 mg once weekly, which is a starting dose rather than a treatment dose, then increasing in 2.5 mg steps no sooner than every four weeks as tolerated, up to a labeled maximum of 15 mg once weekly. Your clinician may stop at a lower maintenance dose if it is working and comfortable.
Do not treat that outline as instructions for yourself. Titration decisions depend on your other medicines, your kidney function, how you tolerate each step and, in practice, on supply. The official prescribing information and medication guide are the authority here, and current label documents are searchable on DailyMed, the NIH label database. A dosing and side effect reference written for patients is also maintained by Mayo Clinic for the subcutaneous route.
Brand pens are single dose and prefilled. Compounded vials are not: they require drawing a volume with a syringe, and the concentration differs between pharmacies. That is where most self injection mistakes happen, so confirm your exact instructions with the prescribing clinic and the pharmacy label rather than with a dosing chart you found online.
Side effects, from common to serious
The most frequent problems are digestive. Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion and reduced appetite show up often in trials, usually strongest in the first days after a dose increase and easing as the body adapts. Injection site reactions, fatigue, burping, hair thinning and heartburn are also reported. Most people who stop early do so because of gut symptoms, not because of a dangerous event.
Less common but more serious risks named in the labeling include inflammation of the pancreas, gallbladder problems including gallstones, acute kidney injury triggered by dehydration from persistent vomiting or diarrhea, serious allergic reactions, and worsening of diabetic eye disease in some people whose blood sugar drops quickly. Labels also warn about food remaining in the stomach during general anesthesia or deep sedation, which raises the risk of aspiration into the lungs. Tell any surgeon, dentist or anesthesia team that you take a weekly GLP-1 medicine.
Longer term questions are still being answered. The class has years of use in diabetes, and this molecule is newer, so nobody can honestly claim a complete picture of decade-scale effects. What is well documented is that muscle loss can accompany rapid weight loss, that gut symptoms often persist at some level for as long as treatment continues, and that appetite suppression tends to fade after stopping. Weight regain after discontinuation is common in published follow up, which is why programs frame this as ongoing treatment rather than a course. You can report a side effect yourself through the FDA MedWatch adverse event program.
Warnings, contraindications and who should not take it
The labeling carries a boxed warning, the strongest warning the FDA uses. In male and female rats, tirzepatide caused thyroid C-cell tumors at exposures relevant to human dosing. Whether it causes those tumors, including medullary thyroid carcinoma, in people is not known, because the human relevance of the rodent finding has not been determined. Because of that uncertainty, the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, and in anyone with Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated after a serious hypersensitivity reaction to the drug. The full boxed warning text sits in the label section further down this page.
Other precautions in the labeling include stopping the medicine if pancreatitis is suspected, and reducing the dose of insulin or an insulin-releasing pill because combining them raises the risk of low blood sugar, including severe episodes. Caution is advised in severe gastrointestinal disease such as gastroparesis, where the stomach already empties too slowly.
Pregnancy is a clear stop point. Animal studies showed fetal harm, weight loss is not appropriate during pregnancy, and the labels advise against use while pregnant. If pregnancy is possible, discuss contraception before starting. People with a history of pancreatitis, gallbladder disease, severe kidney disease, diabetic retinopathy or an eating disorder need a specific conversation rather than a checkbox intake. Weight management labeling also asks clinicians to watch for new or worsening depression or thoughts of self harm.
Interactions and what to tell your clinician
There is no long list of chemical interactions here, but the mechanical ones matter. Because the stomach empties more slowly, absorption of oral medicines can change. That is a practical issue for drugs with a narrow safety window, and worth flagging if you take thyroid hormone, seizure medicines, warfarin or anything where timing is tight.
The most commonly missed interaction is with oral hormonal contraceptives. Diabetes labeling for this molecule advises people using birth control pills to switch to a non-oral method, or to add a barrier method, for four weeks after starting and for four weeks after each dose increase. If nobody mentions that at intake, ask.
Combining the injection with insulin or with sulfonylureas such as glipizide or glimepiride raises hypoglycemia risk, so those doses often need lowering and home glucose monitoring becomes more important. Stacking it with another GLP-1 medicine is not appropriate. Alcohol can add to both low blood sugar risk and nausea. Give the prescriber a full list of prescriptions, over the counter products and supplements, including anything you order online. A patient-facing interaction and monitoring summary is available from Cleveland Clinic’s drug reference. Comparisons with the GLP-1 only option are covered in our Semaglutide Uses and Safety page.
Brand injections versus compounded tirzepatide
Compounded tirzepatide is not an FDA approved product. Compounded medicines are not reviewed by the FDA for safety, effectiveness or manufacturing quality before they are sold, even when the active ingredient in an approved brand is the same molecule. Approval of the brand does not extend to a compounded copy, and the agency has published specific concerns about unapproved GLP-1 products sold for weight loss, including salt forms, untested additives and dosing errors from vials and syringes. Read the agency’s own summary of concerns with unapproved GLP-1 drugs before you decide.
| Factor | Brand injection | Compounded version |
|---|---|---|
| FDA review | Approved, with an official label and medication guide | Not FDA approved or pre-reviewed for quality |
| Form | Prefilled single dose pen or vial | Usually a multi dose vial with a syringe |
| Consistency | Standardized strength across pharmacies | Concentration and additives vary by pharmacy |
| Insurance | May be billable, subject to plan rules | Rarely billable, generally self-pay |
| Legality of copies | Not applicable | Limited to defined circumstances, such as a documented shortage or a clinical change for one patient |
Two pharmacy categories do this work. A 503A pharmacy compounds for one patient against one prescription. A 503B outsourcing facility registers with the FDA, follows stricter manufacturing standards and can supply clinics in batches. Neither status makes a product approved. If a program offers a compounded vial, ask which pharmacy fills it, whether it is 503A or 503B, what the concentration is, whether anything else is mixed in such as vitamin B12, and how the pharmacy handles a quality complaint. Our Medication Index covers the other molecules programs commonly offer, including the brand pages for Mounjaro Diabetes Labeling and Zepbound Weight Indications.
What a month costs and what moves the number
Cash pay and insurance are two separate worlds, and mixing them is how people get surprised. On the self-pay side, the lowest monthly price tracked across programs in our directory is $99, the median lands at $202, and the spread between cheapest and most expensive is $300 across 12 tracked programs. Advertised prices move often, so treat any figure as a snapshot and confirm it at checkout.
Several things drive where a program falls in that range. Brand product costs more than a compounded vial. Dose strength matters, because many programs charge more as you titrate up, and an introductory first month price can jump at renewal. Whether the monthly figure includes the medication, the clinician visit, lab work, shipping and dose changes, or only the membership, changes the comparison completely. Quarterly prepayment usually lowers the monthly figure and raises what you risk if you stop.
On the insurance side, the tracked figure is the plan or membership fee only. Copays and deductibles sit on top and vary by plan and state. Coverage for weight management indications is inconsistent, prior authorization is standard for this class, and denials are common rather than exceptional. Diabetes indications are more often covered than obesity ones. Verify benefits with your own plan before you assume anything; policy research on coverage patterns is published by KFF, an independent health policy organization. To see what a year actually adds up to at a given monthly figure:
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
You can also browse the full Telehealth Provider Directory, read How Our Scoring Works before trusting any ranking, or look at a Sample Savings Report to see what a like-for-like cost comparison includes.
How telehealth programs prescribe it and what varies
Most online programs follow the same broad shape: an intake questionnaire, a review or video visit with a licensed clinician, a prescription if appropriate, then home delivery and monthly check ins. What differs between them is worth more attention than the headline number.
- Whether you get a real clinician visit, and whether you can reach the same person again.
- Whether baseline labs are required, offered, or skipped entirely.
- Whether the program dispenses brand product, compounded vials, or both.
- Which pharmacy fills the order, and whether that pharmacy is named up front.
- How dose increases are handled, and whether each one costs extra.
- What happens if you pause, cancel, or have a side effect that needs a fast answer.
- Whether the program can bill insurance at all, or is self-pay only.
Licensing is state based, so availability and rules differ by where you live, and some states restrict what can be prescribed through an asynchronous questionnaire. Programs that only ever contact you by message may be cheaper and may also be thinner on monitoring. Our Latest Editorial Coverage tracks how these models keep shifting, and the free Health Calculators Hub covers the numbers programs ask about at intake.
Timelines, plateaus and stopping
Blood sugar usually responds within weeks. Weight change is slower, because the dose climbs gradually and the appetite effect strengthens as it does. In the pivotal weight management trials, average reductions were measured over roughly a year and a half at maintenance doses, and averages hide wide individual variation. Nobody can tell you how long a specific number of pounds will take, and any program that promises a rate is overselling. The FDA’s own announcement of the chronic weight management approval is published in its press release archive, and the later sleep apnea decision appears in the agency announcement for that indication.
Plateaus are normal and are not automatically a reason to increase the dose. Protein intake and resistance training matter here, because losing weight quickly means losing some muscle along with fat. To sketch a realistic range for your own starting point:
Weight loss timeline
How long a target is likely to take at a realistic rate, and what the trial percentages would put you at.
Trial averages are not promises: individual response varies widely, and results depend on staying on treatment. Faster than about 2 lb a week usually costs muscle.
Stopping is the part people research too late. There is no withdrawal syndrome, but appetite generally returns, and published follow up shows most people regain a meaningful share of lost weight after discontinuation. If you were also taking diabetes medicines that were reduced, blood sugar can rise again and needs rechecking. Ask before you start what the plan looks like if you stop, whether by choice, because of cost, or because of supply.
Questions worth asking before your first injection
Bring these to the visit rather than the comment section of a forum. Do I have any thyroid cancer history in my family, and does that rule this out for me. Which brand or product am I actually getting, and is it FDA approved or compounded. What labs do you want before and during treatment. Which of my current medicines need adjusting, especially insulin, sulfonylureas or birth control pills. What should I do the week I move up a dose. What counts as a side effect I should call about, and who answers that call on a weekend. What does the total monthly cost include, and what changes at renewal or at a higher dose.
Questions to Ask Before Your First Injection
- Do I have a family history of medullary thyroid carcinoma that contraindicates this drug?
- Which product am I getting - FDA-approved brand or compounded vial?
- What labs are required before and during treatment?
- Which of my current medicines need dose adjustments (insulin, sulfonylureas, birth control pills)?
- What should I do the week I move up a dose?
- What side effects require an urgent call, and who answers on weekends?
- Does the monthly cost include medication, visits, labs, and shipping - or just membership?
When to get medical help quickly
Some symptoms need urgent attention rather than a message and a wait. Get help right away for severe or persistent stomach pain, especially pain that spreads to your back and comes with vomiting, which can signal pancreatitis. Seek emergency care for swelling of the face, lips, tongue or throat, trouble breathing, hives or a rash that spreads, which can signal a serious allergic reaction.
Also call a clinician for vomiting or diarrhea you cannot keep ahead of, since dehydration can injure the kidneys; for pain in the upper right abdomen with fever or yellowing skin, which may point to the gallbladder; for repeated shakiness, sweating, confusion or fainting, which may be low blood sugar if you also take insulin or an insulin-releasing pill; and for sudden vision changes. Tell any surgical or anesthesia team about this medicine well befor
